National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Evolocumab (Repatha®) is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.

Commenced Completed Outcome
12/08/2015 14/08/2015 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
03/11/2015  12/10/2016 Reimbursement Not Recommended

Summary